

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended): A method for softening expression lines on a face and/or forehead in need thereof, comprising topically applying a composition to one or more zones of the face or forehead marked with expression lines a composition comprising at least one compound selected from the group consisting of adenosine and adenosine analogues and a physiologically acceptable medium, wherein the composition comprises 0.1% to 10% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

2. (Original): The method according to Claim 1, wherein said composition comprises an adenosine analogue selected from the group consisting of: agonists of adenosine receptors, compounds increasing intra- or extra-cellular adenosine levels, and mixtures thereof.

3. (Previously Presented): The method according to Claim 1, wherein said composition comprises at least one adenosine analogue selected from the group consisting of: 2'-deoxyadenosine; 2',3'-isopropylidene adenosine; toyocamycin; 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptapurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate and 5'-adenosine triphosphate; phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyladenosine, N⁶-cyclopentyladenosine, 2-chloro-N⁶-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, 5'-N-methylcarboxamido-adenosine, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamidoadenosine, N-ethylcarboxamidoadenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, N⁶-[2-(3,5-

dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine and metrifudil; erythro-9-(2-hydroxy-3-nonyl) adenine and iodotubercidin.

4. (Currently Amended): The method according to claim 1, wherein the composition comprises [[0.01%]] 0.1% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

5. (Currently Amended): The method according to claim 2, wherein the composition comprises [[0.01%]] 0.1% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

6. (Currently Amended): The method according to claim 3, wherein the composition comprises [[0.01%]] 0.1% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

7. (Canceled).

8. (Original): The method of Claim 1, wherein said composition comprises adenosine.

9. (Original): The method of Claim 4, wherein said composition comprises adenosine.

10. (Original): The method according to Claim 1, comprising topically applying to the skin an amount of said composition effective to provide a relaxing effect on contractile fibroblasts.

11. (Original): The method according to Claim 10, wherein said composition comprises an adenosine analogue selected from the group consisting of: agonists of adenosine

receptors, compounds increasing intra- or extra-cellular adenosine levels, and mixtures thereof.

12. (Previously Presented): The method according to Claim 10, wherein said composition comprises at least one adenosine analogue selected from the group consisting of: 2'-deoxyadenosine; 2',3'-isopropylidene adenosine toyocamycin; 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide; 6-methylmercaptapurine riboside; 6-chloropurine riboside; 5'-adenosine monophosphate; 5'-adenosine diphosphate and 5'-adenosine triphosphate; phenylisopropyl adenosine, 1-methylisoguanosine, N⁶-cyclohexyladenosine, N⁶-cyclopentyladenosine, 2-chloro-N⁶-cyclopentyladenosine, 2-chloroadenosine, N⁶-phenyladenosine, 2-phenylaminoadenosine, 5'-N-methylcarboxamido-adenosine, N⁶-phenethyladenosine, 2-p-(2-carboxyethyl)phenethyl-amino-5'-N-ethylcarboxamidoadenosine, N-ethylcarboxamidoadenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, N⁶-[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]adenosine and metrifudil; erythro-9-(2-hydroxy-3-nonyl) adenine and iodotubercidin.

13. (Currently Amended): The method according to claim 10, wherein the composition comprises ~~[[0.01%]]~~ 0.1% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

14. (Currently Amended): The method according to claim 11, wherein the composition comprises ~~[[0.01%]]~~ 0.1% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

15. (Currently Amended): The method according to claim 12, wherein the composition comprises ~~[[0.01%]]~~ 0.1% to 1% by weight of adenosine and/or adenosine analogue with respect to the total composition weight.

16. (Canceled).

17. (Original): The method of Claim 10, wherein said composition comprises adenosine.

18. (Original): The method of Claim 13, wherein said composition comprises adenosine.

19. (Original): The method of Claim 1, wherein said composition comprises adenosine and at least one adenosine analogue.

20. (Original): The method of Claim 10, wherein said composition comprises adenosine and at least one adenosine analogue.

21. (Previously Presented): The method of claim 1, comprising topically applying to the skin an effective amount of said composition to reduce laugh lines and/or reduce frown lines.

22. (Previously Presented): The method of claim 8, comprising topically applying to the skin an effective amount of said composition to reduce laugh lines and/or reduce frown lines.

23. (Currently Amended): A method for softening expression lines on a face and/or forehead in need thereof, comprising topically applying a composition to one or more zones of the face or forehead marked with expression lines a composition comprising adenosine in

Application No. 10/701,495

Response to Office Action dated January 3, 2008

an amount of from ~~[[0.01]]~~ 0.1% to 1% by weight with respect to the total composition and a physiologically acceptable medium.